Compare
Collegium Pharmaceutical vs Lilly (Eli) (COLL vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Collegium Pharmaceutical (COLL) returned -32.5% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are -47.7% and +26.0%.
Lilly (Eli) is the larger company by market value, about 1698.4 times the size of Collegium Pharmaceutical.
On trailing earnings, COLL trades at 24.2 times and LLY at 43.9 times.
Revenue grew +7.7% at COLL and +45.5% at LLY over the last year.
COLL pays no dividend. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| COLL | LLY | |
|---|---|---|
| Price | $24.21 | $1,354.00 |
| 1-day | -3.78% | -0.79% |
| YTD | -47.71% | +25.99% |
| 1 year | -32.47% | +46.25% |
| 3 years | +11.06% | +144.20% |
| Market cap | $750M | $1.27T |
| P/E | 24.2 | 43.9 |
| P/S | 0.92 | 14.73 |
| P/B | 2.54 | 31.63 |
| Revenue growth | +7.70% | +45.50% |
| EPS growth | -37.90% | +50.70% |
| Gross margin % | 59.0 | 83.6 |
| Net margin % | 4.7 | 31.9 |
| ROE % | 12.9 | 68.5 |
| Debt / equity | 0.05 | 1.23 |
| FCF yield % | 44.7 | 2.4 |
| Dividend yield % | — | 0.49 |
| Beta | 0.11 | 0.29 |
| RSI (14) | 56.8 | 61.1 |
| Technical rating |